scholarly article | Q13442814 |
P50 | author | Louis H. Miller | Q1646045 |
Mark C Pierce | Q88672445 | ||
Gregory E.D. Mullen | Q114406008 | ||
Samuel E Moretz | Q114406013 | ||
Ababacar Diouf | Q122675166 | ||
Michael P. Fay | Q48691498 | ||
Kazutoyo Miura | Q66876252 | ||
Carole A Long | Q66908908 | ||
Ruth D Ellis | Q72369361 | ||
P2093 | author name string | Hong Zhou | |
Laura B Martin | |||
P2860 | cites work | Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults | Q21144326 |
The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide | Q21563408 | ||
Invasion of red blood cells by malaria parasites | Q29618806 | ||
Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children | Q33264521 | ||
Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial | Q33264523 | ||
Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria | Q33281394 | ||
The importance of human FcgammaRI in mediating protection to malaria | Q33285037 | ||
Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians | Q33302903 | ||
Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children | Q33319552 | ||
Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria | Q33359552 | ||
Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults | Q33380213 | ||
Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. | Q33394245 | ||
Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria | Q33788306 | ||
Specificity of the protective antibody response to apical membrane antigen 1 | Q34007362 | ||
In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response | Q34260615 | ||
Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity | Q34975629 | ||
Band 3 is a host receptor binding merozoite surface protein 1 during thePlasmodium falciparuminvasion of erythrocytes | Q34982236 | ||
In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized | Q36314049 | ||
A review of human vaccine research and development: malaria | Q36625367 | ||
Plasmodium falciparum malaria vaccines in development | Q37103927 | ||
Intimate molecular interactions of P. falciparum merozoite proteins involved in invasion of red blood cells and their implications for vaccine design | Q37246279 | ||
Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination | Q37459461 | ||
Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. | Q39417737 | ||
Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. | Q40144102 | ||
Characterization of a human reference standard for antibody to Plasmodium falciparum merozoite surface protein 1(42). | Q40413012 | ||
Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells | Q40582637 | ||
Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies | Q41172326 | ||
MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives | Q42605516 | ||
Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes | Q42938913 | ||
A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant | Q46423309 | ||
Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine | Q46852571 | ||
Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya | Q46884256 | ||
Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa | Q47309532 | ||
Gamma-globulin and acquired immunity to human malaria | Q47957467 | ||
P433 | issue | 7 | |
P921 | main subject | antibody | Q79460 |
Plasmodium falciparum | Q311383 | ||
P304 | page(s) | 963-968 | |
P577 | publication date | 2009-05-13 | |
P1433 | published in | Clinical and Vaccine Immunology | Q5133811 |
P1476 | title | Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay | |
P478 | volume | 16 |